{"id":"NCT02799069","sponsor":"Biofrontera Bioscience GmbH","briefTitle":"Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy","officialTitle":"A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of a Nanoemulsion Gel Formulation BF-200 ALA, in Comparison With MetvixÂ® and Placebo, for the Treatment of Actinic Keratosis With PDT","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2016-06-14","resultsPosted":"2017-03-23","lastUpdate":"2017-04-28"},"enrollment":571,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Actinic Keratosis"],"interventions":[{"type":"DRUG","name":"BF-200 ALA","otherNames":["Ameluz"]},{"type":"DRUG","name":"MAL Cream","otherNames":["Metvix","Metvixia"]},{"type":"DRUG","name":"Vehicle","otherNames":["matched placebo to BF-200 ALA gel"]}],"arms":[{"label":"BF-200 ALA","type":"ACTIVE_COMPARATOR"},{"label":"MAL Cream","type":"ACTIVE_COMPARATOR"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The aim of the study is to evaluate the non-inferiority of BF-200 ALA (Ameluz) in the treatment of actinic keratosis (AK) with photodynamic therapy (PDT) compared to Metvix.","primaryOutcome":{"measure":"Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT), ITT","timeFrame":"12 weeks after the last PDT, up to 24 weeks after the first treatment","effectByArm":[{"arm":"Vehicle","deltaMin":17.1,"sd":null},{"arm":"BF-200 ALA","deltaMin":78.2,"sd":null},{"arm":"MAL Cream","deltaMin":64.2,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":"0.0000"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":12},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21910711","23252768"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":76},"commonTop":["Application site irritation","Application site erythema","Application site pain","Application site pruritus","Application site edema"]}}